Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trialResearch in context

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trialResearch in context

Background: With the introduction of glucagon-like peptide-2 (GLP-2) in the treatment of short bowel syndrome (SBS), there is emerging evidence that GLP-2 may play a role in the restoration of the disturbed homeostatic feedback in the gut-liver axis and may ameliorate SBS-associated liver damage.We...

Full description

Bibliographic Details
Main Authors: Rahim Mohammad Naimi, Mark Hvistendahl, Nikolaj Nerup, Rikard Ambrus, Michael Patrick Achiam, Lars Bo Svendsen, Henning Grønbæk, Holger Jon Møller, Hendrik Vilstrup, Adam Steensberg, Palle Bekker Jeppesen
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419304517

Internet

http://www.sciencedirect.com/science/article/pii/S2352396419304517

Similar Items